Roivant Sciences (NASDAQ:ROIV) Given New $33.00 Price Target at The Goldman Sachs Group
Goldman Sachs raised Roivant Sciences' price target from $24.00 to $33.00, maintaining a "buy" rating, suggesting a 50.10% upside. Other analysts also adjusted their targets, with JPMorgan at $20.00, Citigroup at $26.00, and Guggenheim at $25.00. Insider transactions include major shareholder Vivek Ramaswamy selling shares, and institutional investors modifying their holdings. Roivant Sciences focuses on biopharmaceuticals for inflammation and immunology.